The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | MRD in CLL: utility from trials to individuals
John Seymour, MBBS, PhD, of the Peter MacCallum Cancer Center, Victoria, Australia, tells us his thoughts on measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL). Prof. Seymour discusses the utility of MRD for comparing the efficacy of different treatment regimens, and points to its emerging role in the management of individual patients. This interview was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
